Company profile
Editas Medicine, Inc.
NASDAQ: EDIT · Healthcare · Biotechnology
#464 of 1,418 Healthcare companies by revenue70th-percentile growth
EA Score
45DFH 31DQ 55GM 58SS 61
v0.1 · 65/100 weight · provisional
↑ market scale, 3-yr revenue growth · ↓ return on equity, growth stability
Methodology →Revenue TTM
$38.7M
Rev growth YoY (TTM)
+8.0%
Net income (FY)
-$160.1M
Employees
87
as of 2026-08-12
Market cap
$452.7M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$40.5M$40.5M2025
Net income-$160.1M-$160.1M2025
Operating income-$160.0M-$160.0M2025
Total assets$186.5M$186.5M2025
Liabilities$159.2M$159.2M2025
Equity$27.3M$27.3M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Editas Medicine, Inc.’s revenue?
Editas Medicine, Inc. booked $40.5M in FY2025 revenue, growing 25% year over year — faster than most Healthcare companies we track, at a -395.0% net margin.
Peers · Healthcare
Filana Therapeutics, Inc.42DEquillium, Inc.44DMyomo, Inc.53DAlpha Teknova, Inc.58CVoyager Therapeutics, Inc.53DValeo Pharma Inc.——Neighbors
Middlesex →Key facts
CEOGilmore O'Neill
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: EDIT
Employees87
IPO date2016-02-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.